Abstract:Interferon (IFN) induced activities are critical, early determinants of immune responses and infection outcomes. A key facet of IFN responses is the upregulation of hundreds of mRNAs termed interferon-stimulated genes (ISGs) that activate intrinsic and cell-mediated defenses. While primary interferon signaling is well-delineated, other layers of regulation are less explored but implied by aberrant ISG expression signatures in many diseases in the absence of infection. Consistently, our examination of tonic ISG levels across uninfected human tissues and individuals revealed three ISG subclasses. As tissue identity and many comorbidities with increased virus susceptibility are characterized by differences in metabolism, we characterized ISG responses in cells grown in media known to favor either aerobic glycolysis (glucose) or oxidative phosphorylation (galactose supplementation). While these conditions over time had a varying impact on the expression of ISG RNAs, the differences were typically greater between treatments than between glucose/galactose. Interestingly, extended interferon-priming led to divergent expression of two ISG proteins: upregulation of IRF1 in IFN-γ/glucose and increased IFITM3 in galactose by IFN-α and IFN-γ. In agreement with a hardwired response, glucose/galactose regulation of interferon-γ induced IRF1 is conserved in unrelated mouse and cat cell types. In galactose conditions, proteasome inhibition restored interferon-γ induced IRF1 levels to that of glucose/interferon-γ. Glucose/interferon-γ decreased replication of the model poxvirus vaccinia at low MOI and high MOIs. Vaccinia replication was restored by IRF1 KO. In contrast, but consistent with differential regulation of IRF1 protein by glucose/galactose, WT and IRF1 KO cells in galactose media supported similar levels of vaccinia replication regardless of IFN-γ priming. Also associated with glucose/galactose is a seemingly second block at a very late stage in viral replication which results in reductions in herpes- and poxvirus titers but not viral protein expression. Collectively, these data illustrate a novel layer of regulation for the key ISG protein, IRF1, mediated by glucose/galactose and imply unappreciated subprograms embedded in the interferon response. In principle, such cellular circuitry could rapidly adapt immune responses by sensing changing metabolite levels consumed during viral replication and cell proliferation. Early host responses shape virus infection outcomes. Essential and early responses are mediated by signaling initiated by immune cues termed interferons. While the primary steps of activating these immune signaling pathways are well-studied, it is less clear how secondary signals impact antiviral defenses. Modifiers of the immune response are typically viewed as actors that influence the magnitude of the response and output. Metabolism has been implicated in the regulation of antiviral responses in normal and disease contexts; yet, the roles are incompletely understood particularly in non-immune cells. These studies show that metabolic rewiring results in decreased replication of the model poxvirus vaccinia by selectively increasing levels of a key antiviral protein. These data suggest that metabolites might function as secondary cues to alter the composition of the antiviral response to tip infection outcomes. These findings may have relevance for sensing the success of viral replication and shed light on factors contributing to the poor infection outcomes associated with metabolic diseases considered comorbidities.

Viral Growth Factor- And Stat3 Signaling-Dependent Elevation Of The Tca Cycle Intermediate Levels During Vaccinia Virus Infection

Role of vaccinia virus growth factor in stimulating the mTORC1-CAD axis of the de novo pyrimidine pathway under different nutritional cues

Metabolic reprogramming tips vaccinia virus infection outcomes by stabilizing interferon-γ induced IRF1

Metabolic reprogramming tips vaccinia virus infection outcomes by stabilizing interferon-g induced IRF1

Pfkfb3-Driven Macrophage Glycolytic Metabolism Is A Crucial Component Of Innate Antiviral Defense

Vaccinia E5 is a major inhibitor of the DNA sensor cGAS

Palmitic Amide Triggers Virus Life Cycle Via Enhancing Host Energy Metabolism.

Immune Signature of Enhanced Functional Avidity CD8+ T Cells in Vivo Induced by Vaccinia Vectored Vaccine

A Genome-Wide Haploid Genetic Screen Identifies Heparan Sulfate-Associated Genes and the Macropinocytosis Modulator TMED10 as Factors Supporting Vaccinia Virus Infection

The Pi3k/Akt/Mtor Pathway Is Involved In Cvb3-Induced Autophagy Of Hela Cells

Coxsackievirus B3 infection induces glycolysis to facilitate viral replication.

Primary Human Macrophages Serve As Vehicles for Vaccinia Virus Replication and Dissemination

The Role of Tricarboxylic Acid Cycle Metabolites in Viral Infections

Ribosome Profiling Reveals Translational Upregulation of Cellular Oxidative Phosphorylation Mrnas During Vaccinia Virus-Induced Host Shutoff.

Boosting functional avidity of CD8+ T cells by vaccinia virus vaccination depends on intrinsic T-cell MyD88 expression but not the inflammatory milieu.

Identification of Vaccinia Virus Inhibitors and Cellular Functions Necessary for Efficient Viral Replication by Screening Bioactives and FDA-Approved Drugs.

Coxsackievirus B3 Infection Induces Autophagic Flux, and Autophagosomes Are Critical for Efficient Viral Replication.

Synergetic contributions of viral VP1, VP3, and 3C to activation of the AKT-AMPK-MAPK-MTOR signaling pathway for Seneca Valley virus-induced autophagy

Metabolic Reprogramming of the Host Cell by Human Adenovirus Infection

Bovine Parainfluenza Type 3 Virus Induces Incomplete Autophagy to Promote Viral Replication by Activated Beclin1 in Vitro

Metabolic Reprogramming of Host Cells in Response to Enteroviral Infection